Explore Our Services

Strategic CMC Counsel and Execution
Keystone Biologics Advisory provides principal-led CMC counsel across the entire pharmaceutical lifecycle—from the initiation of Phase 1 First-in-Human (FIH) trials through clinical development and final BLA submission.

We work collaboratively with our clients to design phase-appropriate CMC programs. By leveraging a strategic, risk-based approach, we ensure that early-stage programs meet strict FDA expectations without the burden of excessive costs. For later-stage programs, we provide expert guidance on comparability exercises, bridging manufacturing changes to ensure a seamless path to licensure.

Our core service offerings include:

Strategic Drug Development Plans: Designing end-to-end CMC roadmaps tailored to your candidate’s unique profile.

Regulatory Readiness Reviews: Comprehensive assessment of CMC documentation to ensure compliance for IND and BLA submissions.

FDA Engagement Strategy: Providing actionable guidance on timing and addressing critical agency concerns during formal meetings.

Control Strategy Optimization: Aligning manufacturing processes and analytical controls with the latest FDA quality and characterization expectations.

Comparability and Bridging: Devising data-driven strategies to bridge process or site changes throughout development.

Stability and Shelf-Life Management: Authoring robust stability protocols and interpreting data for maximum regulatory impact.

What We Offer

Our Services

TPP · Pre-IND Meetings · IND · BLA · CMC Advisory · Regulatory Strategy ·

TPP · Pre-IND Meetings · IND · BLA · CMC Advisory · Regulatory Strategy ·

  • A well-executed TPP serves as the strategic roadmap for a drug development program. It is an essential foundational document that aligns internal goals and facilitates productive interactions with regulatory agencies.

    Keystone Biologics Advisory collaborates closely with clients to architect the TPP. Through in-depth consultation, we help determine the minimal and preferred acceptance criteria for your medicinal product, ensuring every stage of development is driven by the desired clinical and commercial outcome.

  • Strategic FDA Submissions and Authoring
    Keystone Biologics Advisory provides end-to-end support for FDA regulatory submissions, ensuring technical data is translated into a compelling and compliant narrative. We specialize in authoring and reviewing the Module 3 (CMC) sections for pre-IND meetings, IND applications, and BLA submissions.

    Pre-IND Engagement
    Early, strategic engagement with the FDA is critical to de-risking your development program. We provide expert guidance through the entire pre-IND process:

    • Strategic Advising: Developing a targeted regulatory strategy and identifying critical questions for the agency.

    • Document Authoring: Preparing the pre-IND meeting request and comprehensive briefing book.

    • Agency Interaction: Providing high-level support and attendance during FDA meetings to ensure productive dialogue.

    IND and BLA Submissions
    We navigate the complexities of Module 3 to build robust, phase-appropriate dossiers that align with the latest 2026 FDA flexible framework.

    • Regulatory Readiness: Conducting comprehensive gap analyses of your CMC documentation to identify and remediate risks before submission.

    • Technical Authoring: Full authoring of manufacturing processes, analytical controls, and risk-mitigation strategies.

    • Lifecycle Strategy: Proposing regulatory pathways that facilitate a smooth transition from IND-stage development to final BLA licensure.

    Our goal is to facilitate timely, strategic engagement with the FDA—positioning your program for successful clinical initiation and BLA approval.

  • Keystone Biologics Advisory provides targeted CMC guidance to de-risk development and ensure your program is positioned for regulatory success. Our core service offerings include:

    • CMC Drug Development Plans
      Developing integrated roadmaps that align technical milestones with regulatory expectations from early phase through to commercialization.

    • CMC Readiness Assessments for First-in-Human (FIH)
      Conducting deep-dive evaluations to ensure manufacturing, quality, and safety data meet the threshold for clinical initiation.

    • CMC Gap Analysis for BLA
      Identifying and remediating technical and documentation gaps in preparation for the BLA.

    • Comparability Exercises
      Designing robust comparability protocols to bridge manufacturing changes and scale-up throughout the product lifecycle.

    • Control Strategy and Specifications Development
      Establishing phase-appropriate analytical controls and scientifically justified specifications that meet latest FDA standards.

    • Stability Protocols and Data Review
      Providing expert review of stability programs to ensure data integrity and to support shelf-life justifications for clinical and commercial products.

  • Keystone Biologics Advisory works with clients to prepare a FDA regulatory strategy to facilitate the successful execution of the drug development program. We view FDA designations as more than just regulatory milestones—they are strategic levers.

    We bridge the gap between regulatory status and technical execution, ensuring your manufacturing strategy is as fast and flexible as your clinical pathway.

Request a CMC Strategy Consultation